Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b: Comparison with ligand binding to pCDK2-cyclin a complex

European Journal of Biochemistry

Volumn 271, Issue 11, 2004, Pages 2280-2290

  Kosmopoulou, Magda N ^a   Leonidas, Demetres D ^a   Chrysina, Evangelia D ^a   Bischler, Nicolas ^a   Eisenbrand, Gerhard ^b   Sakarellos, Constantinos E ^c   Pauptit, Richard ^d   Oikonomakos, Nikos G ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^c UNIVERSITY OF IOANNINA   (Greece)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Glycogen phosphorylase; Indirubin 5 sulphonate; Inhibitor; Type 2 diabetes; X ray crystallography

Indexed keywords

ANTINEMATODAL AGENT; GLYCOGEN PHOSPHORYLASE B; INDIRUBIN; INDIRUBIN 5 SULFONATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; KINETICS; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CAFFEINE; CDC2-CDC28 KINASES; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; ENZYME INHIBITORS; FLAVONOIDS; GLUCOSE; GLYCOGEN PHOSPHORYLASE, MUSCLE FORM; INDOLES; LIGANDS; MACROMOLECULAR SUBSTANCES; MODELS, MOLECULAR; MUSCLES; PIPERIDINES; RABBITS; SULFONIC ACIDS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 2942544255     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-1033.2004.04173.x     Document Type: Article

References (43)

1. McCormack, J.G., Westergaard, N., Kristiansen, M., Brand, C.L. & Lau, J. (2001) Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr. Pharm. Des. 7, 1451-1474.
2. Treadway, J.L., Mendys, P. & Hoover, D.J. (2001) Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert. Opin. Invest. Drugs 10, 439-454.
3. Oikonomakos, N.G. (2002) Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. Curr. Protein Pept. Sci. 3, 561-586.
4. Johnson, L.N. (1992) Glycogen phosphorylase: control by phosphorylation and allosteric effectors. FASEB J. 6, 2274-2282.
5. Oikonomakos, N.G., Acharya, K.R. & Johnson, L.N. (1992) Rabbit muscle glycogen phosphorylase b: structural basis of activation and atalysis. In Post-Translational Modification of Proteins (Harding, J.J. & Crabbe, M.J.C., eds), pp. 81-151. CRC Press, Boca Raton, FL.
6. Alemany, S. & Cohen, P. (1986) Phosphorylase a is an allosteric inhibitor of the glycogen and microsomal form of rat hepatic protein phosphatase 1. FEBS Lett. 198, 194-202.
7. Newgard, C.B., Hwang, P.K. & Fletterick, R.J. (1989) The family of glycogen phosphorylases: structure and function. Crit. Rev. Biochem. Mol. Biol. 24, 69-99.
8. Bollen, M. & Stalmans, W. (1992) The structure, role and regulation of Type I protein phosphatases. Crit. Rev. Biochem. Mol. Biol. 27, 227-281.
9. Schnier, J.B., Nishi, K., Monks, A., Gorin, F.A. & Bradbury, E.M. (2003) Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression. Biochem. Biophys. Res. Commun. 309, 126-134.
10. McLaughlin, F., Finn, P. & La Thangue, N.B. (2003) The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov. Today 8, 793-802.
11. Kaiser, A., Nishi, K., Gorin, F.A., Walsh, D.A., Bradbury, E.M. & Schnier, J.B. (2001) The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Biophys. 386, 179-187.
12. Oikonomakos, N.G., Schnier, J.B., Zographos, S.E., Skamnaki, V.T., Tsitsanou, K.E. & Johnson, L.N. (2000) Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 275, 34566-34573.
13. Hoessel, R., Leclerc, S., Endicott, J.A., Nobel, M.E., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., Niederberger, E., Tang, W., Eisenbrand, G. & Meijer, L. (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1, 60-67.
14. Davies, T.G., Tunnah, P., Meijer, L., Marko, D., Eisenbrand, G., Endicott, J.A. & Noble, M.E. (2001) Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 9, 389-397.
15. Leclerc, S., Garnier, M., Hoessel, E., Marko, D., Bibb, J.A., Snyder, G.L., Greengard, P., Biernat, J., Wu, Y.Z., Mandelow, E.M., Eisenbrand, G. & Meijer, L. (2001) Indirubins inhibit glycogen synthase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Aizheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276, 251-260.
16. Meijer, L., Skaltsounis, A.-L., Magiatis, P., Polychronopoulos, P., Knockaert, M., Leost, M., Ryan, X.P., Vonica, C.A., Brivanlou, A., Dajani, R., Crovace, C., Tarricone, C., Musacchio, A., Roe, S.M., Pearl, L. & Greengard, P. (2003) GSK-3-Selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 10, 1255-1266.
17. Polychronopoulos, P., Magiatis, P., Skaltsounis, A.-L., Myrianthopoulos, V., Mikros, E., Tarricone, A., Musacchio, A., Roe, S.M., Pearl, L., Leost, M., Greengard, P. & Meijer, L. (2004) Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 47, 935-946.
18. Oikonomakos, N.G., Kontou, M., Zographos, S.E., Watson, K.A., Johnson, L.N., Bichard, C.J., Fleet, G.W. & Acharya, K.R. (1995) N-acetyl-beta-D- glucopyranosylamine: a potent T-state inhibitor of glycogen phosphorylase. A comparison with alpha-D-glucose. Protein Sci. 4, 2469-2477.
19. Oikonomakos, N.G., Tsitsanou, K.E., Zographos, S.E., Skamnaki, V.T., Goldmann, S. & Bischoff, H. (1999) Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl) -1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate. Protein Sci. 8, 1930-1945.
20. Helmreich, E.J.M. & Cori, C.F. (1964) The role of adenylic acid in the activity of phosphorylase. Proc. Natl Acad. Sci. USA 51, 131-138.
21. Otwinowski, Z. & Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326.
22. French, S. & Wilson, K.S. (1978) On the treatment of the negative intensity observations. Acta Crystallogr. A34, 517-525.
23. Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., GrosseKunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T. & Warren, G.L. (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D54, 905-921.
24. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. (1991) Improved methods for building models in electron density maps & the location of errors in these models. Acta Crystallogr. A 47, 110-119.
25. Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. (1993) PROCHECK - A program to check the stereo-chemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291.
26. CCP4 (1994) The CCP4 suite. Programs for Protein Crystallography. Acta Crystallogr. D 50, 760-763.
27. Read, J. (1986) Improved Fourier coefficient for maps using phases from partial structures with errors. Acta Crystallogr. A 42, 140-149.
28. Hubbard, S.J. & Thornton, J.M. (1993) NACCESS. Department of Biochemistry and Molecular Biology, University College, London.
29. Kraulis, P.J. (1991) MOLSCRIPT - A program to produce both detailed & schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950.
30. Merritt, E.A. & Bacon, D.J. (1997) Raster3D: Photorealistic molecular graphics. Methods Enzymol. B277, 505-524.
31. Kasvinsky, P.J., Shechosky, S. & Fletterick, R.J. (1978) Synergistic regulation of phosphorylase a by glucose and caffeine. J. Biol. Chem. 253, 9102-9106.
32. Madsen, N.B., Shechosky, S. & Fletterick, R.J. (1983) Site-site interactions in glycogen phosphorylase b probed by ligands specific for each site. Biochemistry 22, 4460-4465.
33. Ekstrom, J.L., Pauly, T.A., Carty, M.D., Soeller, W.C., Culp, J., Danley, D.E., Hoover, D.J., Treadway, J.L., Gibbs, E.M., Fletterick, R.J., Day, Y.S., Myszka, D.G. & Rath, V.L. (2002) Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Chem. Biol. 9, 915-924.
34. Sprang, S.R., Fletterick, R.J., Stern, M.J., Yang, D., Madsen, N.B. & Sturtevant, J.S. (1982) Analysis of an allosteric binding site: The nucleoside inhibitor site of phosphorylase a. Biochemistry 21, 2036-2048.
35. Tsitsanou, K.E., Skamnaki, V.T. & Oikonomakos, N.G. (2000) Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug. Arch. Biochem. Biophys. 384, 245-254.
36. Chebotareva, N., Klinov, S.V. & Kurganov, B.I. (2001) Regulation of muscle glycogen phosphorylase by physiological effectors. Biotechnol Genet Eng Rev. 18, 265-297.
37. Kasvinsky, P.J., Fletterick, R.J. & Madsen, N.B. (1981) Regulation of the dephosphorylation of glycogen phosphorylase a and synthase b by glucose and caffeine in isolated hepatocytes. Can. J. Biochem. 59, 387-395.
38. Ercan-Fang, N. & Nuttall, F.Q. (1997) The effect of caffeine and caffeine analogs on rat liver phosphorylase a activity. J. Pharmacol. Exp. Ther. 280, 1312-1318.
39. Noble, M.E. & Endicott, J.A. (1999) Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. Ther 82, 269-278.
40. Bertrand, J.A., Thieffine, S., Vulpetti, A., Cristiani, C., Valsasina, B., Knapp, S., Kalisz, H.M. & Flocco, M. (2003) Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. 333, 393-407.
41. Hudson, J.W., Golding, G.B. & Crerar, M.M. (1993) Evolution of allosteric control in glycogen phosphorylase. J. Mol. Biol. 234, 700-721.
42. McDonald, I.K. & Thornton, J.M. (1994) Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238, 777-793.
43. Nicholls, A. & Honig, B. (1991) A rapid finite difference algorithm, utilising successive over relaxation to solve the Poisson-Boltzmann equation. J. Comput. Chem. 12, 435-445.